ACTIV-2 Clinical Trial Comes to University of Pittsburgh School of Medicine: Investigators Test LY-CoV555 & Potentially Ab8

The University of Pittsburgh School of Medicine (Pitt) represents one of 25 initiated trial site organizations investigating novel therapies targeting the earlier stages of COVID-19 in a bid to start focusing on early treatment to reduce disease progression. Pitt has...

University of Kansas Medical Center Goes All Out in Research Contributing to Beating COVID-19 and Exiting the Pandemic

University of Kansas Medical Center (KUMC) joined the ACTIV-2 clinical trial recently, targeting those patients diagnosed with mild COVID-19 symptoms in a quest to determine how the advanced monoclonal antibody-based product developed by Eli Lilly, LY-COV555, can help...

Pin It on Pinterest